Latest Period
n/a
Security Snapshot
AMAG PHARMACEUTICALS INC - NOTE 3.250% 6/0 Institutional Ownership
CUSIP: 00163UAD8
13F Institutional Holders and Ownership History from Q2 2017 to Q4 2020
Institutions Reporting
Principal
Price (% of par)
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Debt / NOTE 3.250% 6/0
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- 00163UAD8 - AMAG PHARMACEUTICALS INC - NOTE 3.250% 6/0 is tracked under CUSIP 00163UAD8.
- Latest finished 13F holder period is not available.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 20 to 0 between Q3 2020 and Q4 2020.
- SEC-reported value moved from $300,811,000 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
00163UAD8
Latest holder period
n/a
13F holders
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00163UAD8:
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Latest
n/a
Rows shown
1-15 of 15
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2020 Q4 | $0 | $0 | -$288,181,000 | 0 | |
| 2020 Q3 | $327,627,940 | $300,811,000 | +$2,692,371 | 90.07% | 20 |
| 2020 Q2 | $312,441,940 | $249,371,000 | -$2,707,429 | 79.01% | 21 |
| 2020 Q1 | $317,059,940 | $245,459,000 | +$8,999,303 | 77.05% | 22 |
| 2019 Q4 | $304,188,440 | $257,547,955 | -$780,102 | 84.14% | 24 |
| 2019 Q3 | $305,304,940 | $254,761,000 | -$162,879 | 82.44% | 23 |
| 2019 Q2 | $305,562,940 | $247,407,000 | +$14,069,480 | 80.08% | 26 |
| 2019 Q1 | $283,231,440 | $249,512,054 | -$3,064,656 | 87.0% | 28 |
| 2018 Q4 | $291,319,506 | $266,401,370 | -$2,780,250 | 91.43% | 28 |
| 2018 Q3 | $302,125,000 | $316,695,000 | +$4,316,712 | 104.85% | 26 |
| 2018 Q2 | $289,287,500 | $297,889,550 | -$2,098,020 | 102.67% | 27 |
| 2018 Q1 | $291,464,000 | $300,997,153 | +$8,064,568 | 103.06% | 33 |
| 2017 Q4 | $292,370,000 | $251,949,000 | -$2,117,878 | 86.12% | 32 |
| 2017 Q3 | $290,390,000 | $282,871,000 | -$23,277,339 | 97.25% | 34 |
| 2017 Q2 | $314,557,000 | $302,501,000 | +$302,500,500 | 96.12% | 34 |